Dyadic Reports 2023 Full Year Results and Recent Company Progress
“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
- “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
- We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
- For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
- Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.